Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.?

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio? (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi? (encorafinib) + Mektovi? (binimetinib)?: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
  • giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
  • Ibrance? (palbociclib): High Risk Early Breast Cancer
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
  • Talzenna? (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz? (tofacitinib): Ankylosing Spondylitis
  • Xtandi? (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of July 28, 2020

  • Discovery Projects
  • Phase 1
    25
  • Phase 2
    38
  • Phase 3
    23
  • Registration
    4
  • Total90
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (adult) (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (infants) (FAST TRACK)
Project advanced
Phase 3 Product Enhancement Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY Meningococcal Infections (adolescent and young adults)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-07302048 (BNT162)
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
Go to clinical trial
COVID-19 Infection (in partnership with BioNTech) (FAST TRACK) (Pivotal Phase 2/3 global study)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive Group B Streptococcus Infection (maternal) Phase 2 New Molecular Entity Vaccine
PF-07307405
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Lyme disease
Project advanced
Phase 2 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (infants and children) Phase 2 New Molecular Entity Vaccine
PF-06881894, a potential biosimilar to Neulasta? (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (E.U.) Registration Biosimilar Biosimilar
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Metastatic Castration Sensitive Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) (E.U.)
Project advanced
Registration Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/cytarabine and daunorubicin in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
ER+/HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic